Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 2/2015

01.03.2015 | Pros and Cons in Endocrine Practice

Metformin in women with PCOS, CONS

verfasst von: Marie L. Misso, Helena J. Teede

Erschienen in: Endocrine | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Metformin has a potential role for insulin resistance in polycystic ovary syndrome(PCOS) and has demonstrated efficacy in diabetes. There are a large number of studies and evidence syntheses comparing metformin with control, lifestyle interventions, the oral contraceptive pill, and clomiphene citrate; however, there is still uncertainty about the effectiveness of metformin in women with PCOS. Here we present a systematic overview of the evidence for the use of metformin in women with PCOS. The evidence suggests that metformin continues to have an unclear roll in PCOS until further well designed; methodologically rigorous effectiveness studies with large sample sizes are conducted, and these should include women across the body mass index (BMI) range.
Literatur
1.
W.A. March, V.M. Moore, K.J. Willson, D.I. Phillips, R.J. Norman, M.J. Davies, The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25(2), 544–551 (2010). doi:10.​1093/​humrep/​dep399 CrossRefPubMed
2.
J.A. Boyle, J. Cunningham, K. O’Dea, T. Dunbar, R.J. Norman, Prevalence of polycystic ovary syndrome in a sample of indigenous women in Darwin, Australia. Med. J. Aust. 196(1), 62–66 (2012)CrossRefPubMed
3.
S.R. Davis, S. Knight, V. White, C. Claridge, B.J. Davis, R. Bell, Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecol. Endocrinol. 16(6), 443–446 (2002)CrossRefPubMed
4.
M. Hickey, D.A. Doherty, H. Atkinson, D.M. Sloboda, S. Franks, R.J. Norman, R. Hart, Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum. Reprod. 26(6), 1469–1477 (2011). doi:10.​1093/​humrep/​der102 CrossRefPubMed
5.
6.
B.O. Yildiz, G. Bozdag, Z. Yapici, I. Esinler, H. Yarali, Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. (Oxford, England) 27(10), 3067–3073 (2012)CrossRef
7.
R.J.R.J. Norman, D.D. Dewailly, R.S.R.S. Legro, T.E.T.E. Hickey, Polycystic ovary syndrome. Lancet 370(9588), 685–697 (2007)CrossRefPubMed
8.
H.J. Teede, A.E. Joham, E. Paul, L.J. Moran, D. Loxton, D. Jolley, C. Lombard, Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity (2013). doi:10.​1002/​oby.​20213
9.
H.J. Teede, M.L. Misso, A.A. Deeks, L.J. Moran, B.G. Stuckey, J.L. Wong, R.J. Norman, M.F. Costello, Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med. J. Aust. 195(6), S65–S112 (2011)CrossRefPubMed
10.
N.K. Stepto, S. Cassar, A.E. Joham, S.K. Hutchison, C.L. Harrison, R.F. Goldstein, H.J. Teede, Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum. Reprod. 28(3), 777–784 (2013)CrossRefPubMed
11.
12.
L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16(4), 347–363 (2010)CrossRefPubMed
13.
R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, W. Futterweit, R. Lobo, R.J. Norman, E. Talbott, D.A. Dumesic, Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95(5), 2038–2049 (2010). doi:10.​1210/​jc.​2009-2724 CrossRefPubMed
14.
15.
A.A. Deeks, M.E. Gibson-Helm, E. Paul, H.J. Teede, Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression? Hum. Reprod. 26(6), 1399–1407 (2011)CrossRefPubMed
16.
L.C. Giudice, Endometrium in PCOS: implantation and predisposition to endocrine CA. Best. Pract. Res. Clin. Endocrinol. Metab. 20(2), 235–244 (2006)CrossRefPubMed
17.
B.C.J.M. Fauser, B.C. Tarlatzis, R.W. Rebar, R.S. Legro, A.H. Balen, R. Lobo, E. Carmina, J. Chang, B.O. Yildiz, J.S.E. Laven, J. Boivin, F. Petraglia, C.N. Wijeyeratne, R.J. Norman, A. Dunaif, S. Franks, R.A. Wild, D. Dumesic, K. Barnhart, Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97(1), 28–38 (2012)CrossRefPubMed
18.
H.J. Teede, A.E. Joham, E. Paul, L.J. Moran, D. Loxton, D. Jolley, C. Lombard, Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity 21(8), 1526–1532 (2013)CrossRefPubMed
19.
20.
PCOS Australian Alliance: Evidence based guidelines for assessment and management of polycystic ovary syndrome. In: Jean Hailes Foundation for Women’s Health on behalf of the PCOS Australian Alliance Melbourne (2011)
21.
R.S. Legro, S.A. Arslanian, D.A. Ehrmann, K.M. Hoeger, M.H. Murad, R. Pasquali, C.K. Welt, Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 98(12), 4565–4592 (2013). doi:10.​1210/​jc.​2013-2350 CrossRefPubMed
22.
T. Bridger, S. MacDonald, F. Baltzer, C. Rodd, Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch. Pediatr. Adolesc. Med. 160(3), 241–246 (2006)CrossRefPubMed
23.
L. Morin-Papunen, A.S. Rantala, L. Unkila-Kallio, A. Tiitinen, M. Hippelainen, A. Perheentupa, H. Tinkanen, R. Bloigu, K. Puukka, A. Ruokonen, J.S. Tapanainen, Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J. Clin. Endocrinol. Metab. 97(5), 1492–1500 (2012). doi:10.​1210/​jc.​2011-3061 CrossRefPubMed
24.
D. Romualdi, M. Giuliani, F. Cristello, A.M. Fulghesu, L. Selvaggi, A. Lanzone, M. Guido, Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil. Steril. 93(7), 2303–2310 (2010). doi:10.​1016/​j.​fertnstert.​2009.​01.​114 CrossRefPubMed
25.
M. Costello, B. Shrestha, J. Eden, P. Sjoblom, N. Johnson, Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst. Rev. (1), CD005552 (2007)
26.
Z. Jing, X. Liang-Zhi, W. Tai-Xiang, T. Ying, J. Yu-Jian, The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Gynecol. Endocrinol. 24(10), 590–600 (2008). doi:10.​1080/​0951359080228824​2 CrossRefPubMed
27.
C. Meyer, B. McGrath, H. Teede, Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30, 471–478 (2007)CrossRefPubMed
28.
D.D.G. Curi, A.M. Fonseca, J.A.M. Marcondes, J.A.M. Almeida, V.R. Bagnoli, J.M. Soares Jr, E.C. Baracat, Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecol. Endocrinol 28(3), 182–185 (2012). doi:10.​3109/​09513590.​2011.​583957 CrossRefPubMed
29.
K.A. Martin, R.J. Chang, D.A. Ehrmann, L. Ibanez, R.A. Lobo, R.L. Rosenfield, J. Shapiro, V.M. Montori, B.A. Swiglo, Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(4), 1105–1120 (2008). doi:10.​1210/​jc.​2007-2437 CrossRefPubMed
30.
T. Tang, J.M. Lord, R.J. Norman, E. Yasmin, A.H. Balen, Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 5, CD003053 (2012). doi:10.​1002/​14651858.​CD003053.​pub5
31.
M. Luque-Ramirez, F. Alvarez-Blasco, J.I. Botella-Carretero, E. Martinez-Bermejo, M.A. Lasuncion, H.F. Escobar-Morreale, Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92(7), 2453–2461 (2007)CrossRefPubMed
32.
K.M. Hoeger, L. Kochman, N. Wixom, K. Craig, R.K. Miller, D.S. Guzick, A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil. Steril. 82(2), 421–429 (2004)CrossRefPubMed
33.
H.S. Qublan, E.K. Yannakoula, M.A. Al-Qudah, F.I. El-Uri, Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. Saudi Med. J. 28(11), 1694–1699 (2007)PubMed
34.
K. Hoeger, K. Davidson, L. Kochman, T. Cherry, L. Kopin, D.S. Guzick, The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab. 93(11), 4299–4306 (2008). doi:10.​1210/​jc.​2008-0461 CrossRefPubMedCentralPubMed
35.
P. Popova, E. Ryasantseva, I. Zazerskaya, L. Ivanova, E. Grineva, The role of weight loss and metformin in the improvement of menstrual function in overweight and obese women with polycystic ovary syndrome. Diabetes, Obes. Metab. 12, 87 (2010). doi:10.​1111/​j.​1463-1326.​2010.​01284.​x
36.
R. Pasquali, A. Gambineri, D. Biscotti, V. Vicennati, L. Gagliardi, D. Colitta, S. Fiorini, G.E. Cognigni, M. Filicori, A.M. Morselli-Labate, Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85(8), 2767–2774 (2000)CrossRefPubMed
37.
X. Sun, D. Zhang, W. Zhang, Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch. Gynecol. Obstet. 288(2), 423–430 (2013). doi:10.​1007/​s00404-013-2756-5 CrossRefPubMed
38.
T.I. Siebert, M.I. Viola, D.W. Steyn, T.F. Kruger, Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. Gynecol. Obstet. Invest. 73(4), 304–313 (2012). doi:10.​1159/​000335253 CrossRefPubMed
39.
40.
41.
S. Kar, Clomiphene citrate, metformin or the combination of both, as first line ovulation induction drug in polycystic ovarian syndrome: a randomised controlled trial. Fertil. Steril 1, S359–S360 (2013). doi:10.​1016/​j.​fertnstert.​2013.​07.​849
42.
43.
S. Palomba, A. Falbo, G.B. La Sala, Clomiphene citrate, metformin or both for ovulation induction in therapy naive women with polycystic ovary syndrome (PCOS)? A descriptive review. Curr. Drug Ther. 8(1), 30–37 (2013). doi:10.​2174/​1574885511308010​004 CrossRef
44.
R.C. Machado, N.A. Machado, S. Geber, Evaluation of the use of metformin in ovulation result of patients with the polycystic ovary syndrome resistant to isolated use of clomiphene citrate. Jornal Brasileiro de Reproducao Assistida 16(1), 27–31 (2012)
45.
M.L. Misso, M.F. Costello, M. Garrubba, J. Wong, R. Hart, L. Rombauts, A.M. Melder, R.J. Norman, H.J. Teede, Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 19(1), 2–11 (2013). doi:10.​1093/​humupd/​dms036 CrossRefPubMed
46.
47.
M.S. Alebic, T. Bulum, N. Stojanovic, L. Duvnjak, Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine (2014). doi:10.​1007/​s12020-014-0182-5 PubMed
48.
R.E. Ratner, C.A. Christophi, B.E. Metzger, D. Dabelea, P.H. Bennett, X. Pi-Sunyer, S. Fowler, S.E. Kahn, Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J. Clin. Endocrinol. Metab. 93(12), 4774–4779 (2008). doi:10.​1210/​jc.​2008-0772 CrossRefPubMedCentralPubMed
49.
F. Esfahanian, M.M. Zamani, R. Heshmat, Moini nia, F.: Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. J Obstet Gynaecol Res 39(4), 806–813 (2013). doi:10.​1111/​j.​1447-0756.​2012.​02051.​x CrossRefPubMed
50.
W. Knowler, E. Barrett-Connor, S. Fowler, R. Hamman, J. Lachin, E. Walker, D. Nathan, Diabetes Prevention Program Research Group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393–403 (2002)CrossRefPubMed
51.
J.L. Rosenzweig, E. Ferrannini, S.M. Grundy, S.M. Haffner, R.J. Heine, E.S. Horton, R. Kawamori, Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(10), 3671–3689 (2008). doi:10.​1210/​jc.​2008-0222 CrossRefPubMed
52.
J.P. Domecq, G. Prutsky, R.J. Mullan, V. Sundaresh, A.T. Wang, P.J. Erwin, C. Welt, D. Ehrmann, V.M. Montori, M.H. Murad, Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 98(12), 4646–4654 (2013). doi:10.​1210/​jc.​2013-2374 CrossRefPubMed
53.
Metadaten
Titel
Metformin in women with PCOS, CONS
verfasst von
Marie L. Misso
Helena J. Teede
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0394-8

Weitere Artikel der Ausgabe 2/2015

Endocrine 2/2015 Zur Ausgabe

Editorial

Albuminuria in prediabetes: time to intervene?

Original Article

Relationship between dyslipidemia and albuminuria in prediabetic adults: The Korea National Health and Nutrition Examination Survey 2011–2012

Review

A four-season molecule: osteocalcin. Updates in its physiological roles

Endocrine Imaging

Metastasis to the thyroid from non-small cell carcinoma of the lung: findings in 18F-FDG PET/CT study

Viewpoint

Remission of type 2 diabetes: is bariatric surgery ready for prime time?

Research Letter

Insulin-like factor 3 plasma levels in acromegaly before and after somatostatin analog treatment

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise